Search

Your search keyword '"Steinberg, S.M."' showing total 143 results
Start Over Author "Steinberg, S.M."
143 results on '"Steinberg, S.M."'

7. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports

Author

Toro, J.R., Wei, M.-H., Glenn, G.M., Weinreich, M., Toure, O., Vocke, C., Turner, M., Choyke, P., Merino, M.J., Pinto, P.A., Steinberg, S.M., Schmidt, L.S., and Linehan, W.M.

Subjects
Skin diseases -- Genetic aspects, Skin diseases -- Development and progression, Genetic disorders -- Research, Gene mutations -- Analysis, Health
Published
2008

8. Vapor adsorption of trichloroethylene on quartz sands of varying grain size

Author

Kreamer, David K., Steinberg, S.M., and Phillips, Hugh

Subjects
Vapors -- Research, Adsorption -- Research, Trichloroethylene -- Research, Sand -- Research, Engineering and manufacturing industries, Environmental issues
Abstract

Laboratory measurements were carried out to determine the vapor adsorption of the solvent trichloroethylene (TCE) on a dry quartz sand of two different mesh sizes. Using a static adsorption laboratory procedure and inverse gas chromatography (IGC), the sorption of TCE vapor in nitrogen was measured at concentration ranges of approximately 0.1 to 440,000 ppm by volume. Adsorption was measured on 30/40 and 100/200 mesh dry quartz sand, with the finer material created by mechanically crushing and sieving coarser material. The observed sorption isotherms fit a Freundlich isotherm and are also well represented by a simple linear sorption isotherm.

Published
1994

9. PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-CELL LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Author

Melani, C.J., primary, Lakhotia, R., additional, Pittaluga, S., additional, Miljkovic, M.D., additional, Portell, C.A., additional, Farah, R.J., additional, Juanitez, A.M., additional, Chou, L.L., additional, Steinberg, S.M., additional, Jaffe, E.S., additional, Staudt, L.M., additional, Roschewski, M.J., additional, and Wilson, W.H., additional

Published
2019
Full Text
View/download PDF

11. Radiation As a Local Ablative Therapy Option for Oligoprogressive EGFR-Mutant Non-Small Cell Lung Cancer after Treatment with Osimertinib

Author

Kesarwala, A.H., primary, Kim, C., additional, Jones, J.C., additional, Kaushal, A., additional, Roper, N., additional, Hoang, C.D., additional, Szabo, E., additional, Connolly, M., additional, Padiernos, E., additional, Cultraro, C., additional, Waris, M., additional, Gao, S., additional, Steinberg, S.M., additional, Khan, J., additional, Rajan, A., additional, and Guha, U., additional

Published
2017
Full Text
View/download PDF

12. Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies

Author

Nadal, R., primary, Mortazavi, A., additional, Stein, M., additional, Pal, S.K., additional, Davarpanah, N., additional, Parnes, H.L., additional, Ning, Y.M., additional, Cordes, L.M., additional, Lin, J., additional, Bagheri, M., additional, Linderberg, L., additional, Berniger, M., additional, Steinberg, S.M., additional, Moore, T., additional, Lancaster, T., additional, Aviles, M., additional, Costello, R., additional, Bottaro, D.P., additional, Dahut, W.L., additional, and Apolo, A.B., additional

Published
2017
Full Text
View/download PDF

13. RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA-EPOCH-R

Author

Dunleavy, K., primary, Roschewski, M., additional, Abramson, J.S., additional, Link, B., additional, Parekh, S., additional, Jagadeesh, D., additional, Bierman, P., additional, Watson, P.R., additional, Peace, D., additional, Hanna, W., additional, Powell, B., additional, Melani, C., additional, Lucas, A., additional, Steinberg, S.M., additional, Kahl, B., additional, Friedberg, J.W., additional, Little, R.F., additional, Bartlett, N.L., additional, Fanale, M.A., additional, Noy, A., additional, and Wilson, W.H., additional

Published
2017
Full Text
View/download PDF

14. A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors

Author

Apolo, A.B., primary, Mortazavi, A., additional, Stein, M., additional, Pal, S.K., additional, Davarpanah, N., additional, Parnes, H.L., additional, Ning, Y.M., additional, Francis, D.C., additional, Cordes, L.M., additional, Berniger, M., additional, Steinberg, S.M., additional, Monk, P., additional, Lancaster, T., additional, Mayer, T., additional, Costello, R., additional, Bottaro, D.P., additional, and Dahut, W.L., additional

Published
2016
Full Text
View/download PDF

15. A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)

Author

Nadal, R., primary, Parnes, H.L., additional, Francis, D.C., additional, Cordes, L.M., additional, Berninger, M., additional, Costello, R., additional, Folio, L., additional, Linderberg, M., additional, Machado, L., additional, Steinberg, S.M., additional, Wright, J.J., additional, Ning, Y.M., additional, Bottaro, D.P., additional, Dahut, W.L., additional, and Apolo, A.B., additional

Published
2016
Full Text
View/download PDF

16. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer

Author

Duffy, A.G., primary, Makarova-Rusher, O.V., additional, Ulahannan, S.V., additional, Rahma, O.E., additional, Fioravanti, S., additional, Walker, M., additional, Abdullah, S., additional, Raffeld, M., additional, Anderson, V., additional, Abi-Jaoudeh, N., additional, Levy, E., additional, Wood, B.J., additional, Lee, S., additional, Tomita, Y., additional, Trepel, J.B., additional, Steinberg, S.M., additional, Revenko, A.S., additional, MacLeod, A.R., additional, Peer, C.J., additional, Figg, W.D., additional, and Greten, T.F., additional

Published
2016
Full Text
View/download PDF

17. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

Author

Carter, C.A., primary, Rajan, A., additional, Keen, C., additional, Szabo, E., additional, Khozin, S., additional, Thomas, A., additional, Brzezniak, C., additional, Guha, U., additional, Doyle, L.A., additional, Steinberg, S.M., additional, Xi, L., additional, Raffeld, M., additional, Tomita, Y., additional, Lee, M.J., additional, Lee, S., additional, Trepel, J.B., additional, Reckamp, K.L., additional, Koehler, S., additional, Gitlitz, B., additional, Salgia, R., additional, Gandara, D., additional, Vokes, E., additional, and Giaccone, G., additional

Published
2016
Full Text
View/download PDF

18. NIH lung score components are associated with clinical outcomes, Bronchiolitis obliterans syndrome and survival in chronic GvHD

Author

Grkovic, L., Pulanic, D., Steinberg, S.M., Williams, K.M., Baird, K., Mitchell, S.A., Cowen, E.W., Datiles, M.B., Aria, D., Bassim, C., Joe, G., Comis, L., Baruffaldi, J., Zhang, D., Sportes, C., Fowler, D.H., Hakim, F., Gress, R.E., and Pavletic, S.Z.

Subjects
otorhinolaryngologic diseases, chronic graft versus host disease, severity, lung score, humanities
Abstract

Objectives: NIH chronic GVHD (cGVHD) consensus project proposed NIH lung score (NIHLs) 0-3 as a measure of cGVHD severity (BBMT 2005 ; 11:945). NIHLs is composed of 3 components: respiratory symptoms (RS), FEV1 and lung function score (LFS) devised from DLCO and FEV1. The final NIHLs (0-3) is determined by maximum of individual components. The goal of this study was to evaluate associations of NIHLs components and clinical outcomes. Methods: 211 cGVHD patients (pts), median age 48y (18-70), enrolled 2004-2011 into the NCI natural history study, with median follow-up for survivors of 36 months. Pts received 3 (0– 9) prior systemic therapies (PST). 66% had severe and 32% moderate NIH global cGVHD severity ; median 5 (1-8) organs were involved. 42% had mild, 26% moderate and 10% severe NIHLs. 46 pts had bronchiolitis obliterans syndrome (BOS) by modifi ed NIH criteria (BBMT 2010 ; 16:S106). Measures were obtained at study entry: NIHLs, SF36 (PCS, MCS), Lee symptom scale (total and breathing), HAP (MAS, AAS), walk velocity, grip strength, cGVHD activity, intensity of immunosuppression, number of PST, cGVHD severity by clinician and patient (0-10). Results: FEV1 and LFS were weakly to moderately correlated with 8-9 outcome measures (|r| >0.30) ; DLCO with grip strength, AAS and walk velocity (|r| >0.30), and increasing RS and NIHLs was associated with 11 and 12 outcomes respectively (p

Published
2012

20. Chronic Graft-Versus-Host Disease (cGVHD) Patients with Bronchiolitis Obliterans Syndrome (BOS) Have Worse Clinical Manifestations and Severity of cGVHD with More Impairment in Self- Assessed Physical and Mental Health than cGVHD Patients without BOS

Author

Grkovic, L., Pulanic, D., Steinberg, S.M., Williams, K.M., Baird, K., Mitchell, S.A., Cowen, E.W., Datiles, M.B., Bassim, C.W., Galen, J., Comis, L., Avila, D.N., Taylor, T.N., Zhang, D., Cole, K., Fowler, D.H., Hakim, F.T., Gress, R.E., and Pavletic, S.Z.

Subjects
immune system diseases, hemic and lymphatic diseases, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome, severity, humanities
Abstract

Background: One of the most severe manifestations of cGVHD is bronchiolitis obliterans syndrome (BOS), an insidious lung disease occurring in a subset of patients after allogeneic HSCT, characterized by progressive circumferential fibrosis and cicatrization of the small terminal airways. Since BOS is morbid and frequently fatal complication, insight into the features that distinguish those patients with cGVHD who develop BOS from those who do not could be important in better understanding of the disease and its clinical implications, and may lead to developing of new treatment modalities and strategies. The aim of this study was to compare demographic characteristics, clinical manifestations, laboratory parameters, functional and psychological status, activity and severity of cGVHD, and overall survival (OS) between cGVHD patients with and without BOS. Methods: 46 adult cGVHD patients with BOS (diagnosed using modified NIH criteria as: FEV1=50, 78% for patients without BOS, and 37% for patients with BOS and FEV1< 50%, respectively. Conclusion: cGVHD patients with BOS had worse clinical manifestations and cGVHD severity as well as inferiorities in functioning and self- assessed physical and mental health. The impact of BOS on survival was restricted to an effect of FEV1

Published
2012

21. Oral Disease Profiles in Chronic Graft versus Host Disease

Author

Bassim, C.W., primary, Fassil, H., additional, Mays, J.W., additional, Edwards, D., additional, Baird, K., additional, Steinberg, S.M., additional, Cowen, E.W., additional, Naik, H., additional, Datiles, M., additional, Stratton, P., additional, Gress, R.E., additional, and Pavletic, S.Z., additional

Published
2015
Full Text
View/download PDF

22. 846O - Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies

Author

Nadal, R., Mortazavi, A., Stein, M., Pal, S.K., Davarpanah, N., Parnes, H.L., Ning, Y.M., Cordes, L.M., Lin, J., Bagheri, M., Linderberg, L., Berniger, M., Steinberg, S.M., Moore, T., Lancaster, T., Aviles, M., Costello, R., Bottaro, D.P., Dahut, W.L., and Apolo, A.B.

Published
2017
Full Text
View/download PDF

23. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab. Initial experience

Author

Thukral, A. (Arpi), Thomasson, D.M. (David M.), Chow, C.K. (Catherine K.), Garcia-de-Eulate, R. (Reyes), Wedam, S.B. (Suparna B.), Gupta, S.N. (Sandeep N.), Wise, B.J. (Betty J.), Steinberg, S.M. (Seth M.), Liewehr, D.J. (David J.), Choyke, P.L. (Peter L.), and Swain, S.M. (Sandra M.)

Subjects
Contrast Media/pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols, Magnetic Resonance Imaging
Abstract

To retrospectively compare three dynamic contrast material-enhanced magnetic resonance (MR) imaging (dynamic MR imaging) analytic methods to determine the parameter or combination of parameters most strongly associated with changes in tumor microvasculature during treatment with bevacizumab alone and bevacizumab plus chemotherapy in patients with inflammatory or locally advanced breast cancer. MATERIALS AND METHODS: This study was conducted in accordance with the institutional review board of the National Cancer Institute and was compliant with the Privacy Act of 1974. Informed consent was obtained from all patients. Patients with inflammatory or locally advanced breast cancer were treated with one cycle of bevacizumab alone (cycle 1) followed by six cycles of combination bevacizumab and chemotherapy (cycles 2-7). Serial dynamic MR images were obtained, and the kinetic parameters measured by using three dynamic analytic MR methods (heuristic, Brix, and general kinetic models) and two region-of-interest strategies were compared by using two-sided statistical tests. A P value of .01 was required for significance. RESULTS: In 19 patients, with use of a whole-tumor region of interest, the authors observed a significant decrease in the median values of three parameters measured from baseline to cycle 1: forward transfer rate constant (Ktrans) (-34% relative change, P=.003), backflow compartmental rate constant extravascular and extracellular to plasma (Kep) (-15% relative change, P

Published
2007

24. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma

Author

Wilson, W.H. (Wyndham), Bromberg, J.E.C. (Jacoline), Stetler-Stevenson, M. (Maryalice), Steinberg, S.M. (Seth), Martin-Martin, L. (Lourdes), Muñiz, C. (Carmen), Sancho, J.M. (Juan Manuel), Caballero, L., Davidis, M.A. (Marjan), Brooimans, R.A. (Rik), Sanchez-Gonzalez, B. (Blanca), Salar, A. (Antonio), González-Barca, E. (Eva), Ribera, J.M. (Josep Maria), Shovlin, M. (Margaret), Filie, A. (Armando), Dunleavy, K. (Kieron), Mehrling, T. (Thomas), Spina, M. (Michele), Orfao, A. (Alberto), Wilson, W.H. (Wyndham), Bromberg, J.E.C. (Jacoline), Stetler-Stevenson, M. (Maryalice), Steinberg, S.M. (Seth), Martin-Martin, L. (Lourdes), Muñiz, C. (Carmen), Sancho, J.M. (Juan Manuel), Caballero, L., Davidis, M.A. (Marjan), Brooimans, R.A. (Rik), Sanchez-Gonzalez, B. (Blanca), Salar, A. (Antonio), González-Barca, E. (Eva), Ribera, J.M. (Josep Maria), Shovlin, M. (Margaret), Filie, A. (Armando), Dunleavy, K. (Kieron), Mehrling, T. (Thomas), Spina, M. (Michele), and Orfao, A. (Alberto)

Abstract

The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk of central nervous system disease is controversial. Furthermore, the effect of intrathecal treatment and rituximab in diffuse large B-cell and Burkitt lymphoma with occult leptomeningeal disease detected by flow cytometry at diagnosis is unknown. Untreated diffuse large B-cell (n=246) and B

Published
2014
Full Text
View/download PDF

25. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer

Author

Sanz Ortega, J., Steinberg, S.M., Moro, E., Saez, M., Lopez, J.A., Sierra, E., Sanz Esponera, J., and Merino, M.J.

Subjects
6 - Ciencias aplicadas::61 - Medicina [CDU], Angiogenesis, Prognosis
Abstract

Gastric cancer (GC) continues to be a highly aggressive malignancy with poor prognosis and low survival rates. The survival of patients with GC depends mainly on the stage of the disease, with early GC having a 5 year survival of 90-100% and advanced tumors a 5 year survival of 15-25%. The role of other prognostic factors in these tumors is still under investigation. 28 gastric dysplasia, 45 Early GC and 98 Advanced Gastric Cancers were evaluated for expression of the oncogenes p53, c-ErbB2, c-myc and the EGFr in paraffin-embedded material utilizing Avidin-Biotin immunohistochemistry techniques. In 34 cases of GC microvessel density (MVD) was determined in CD34 stained sections. Statistical correlations with stage, histologic type, differentiation degree, location, size, ploidy patterns and overall survival were done. The Mantel-Cox test was performed to evaluate which factors had an independent prognostic value. Both, tumor angiogenesis and p53 protein expression were statistically associated (95% confidence intervals) with overall survival in patients with GC. p53 protein expression was also correlated with cardial location, nodal involvement and tumor stage. c-ErbB2 may recognize a group of highly aggressive well differentiated adenocarcinomas with worse prognosis. c-myc was also significantly enhanced in well differentiated tumors. EGFr showed no significant associations. Mantel-Cox was performed to compare the prognostic value of tumor stage, p53 protein expression and tumor angiogenesis. Tumor angiogenesis was the most important prognostic indicator to predict overall survival in our series. p53 expression was not independent and did not provide additional prognostic information to tumor stage. Our study suggests that angiogenesis as demonstrated by microvessel counts in CD34 stained sections is a significantly important Offprint requests to: Julian Sanz Ortega, MD, Departamento de Anatomia Patolbgica, Hospital Universitario "San Carlos". Martin Lagos s.n., Madrid 28040, Spain. Fax: 34-913303032, e-mail: jsanz@ hcsc.insalud.es prognostic factor for predicting survival in gastric cancer.

Published
2000

30. Intentional Ingestion of Foreign Bodies and Psychiatric Disease Among Prisoners

Author

Jones, C., primary, McGonagle, E.A., additional, Stawicki, S.P., additional, Otey, A.J., additional, Dalal, P.P., additional, Whitmill, M.L., additional, Levine, E.J., additional, McKimmie, R.L., additional, Papadimos, T.J., additional, Steinberg, S.M., additional, Cook, C.H., additional, Bergese, S.D., additional, and Evans, D.C., additional

Published
2014
Full Text
View/download PDF

31. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

Author

Sissung, T.M. (Tristan), Danesi, R. (Romano), Price, D.K. (Douglas), Steinberg, S.M. (Seth), Wit, R. (Ronald) de, Zahid, M. (Muhammad), Gaikwad, N. (Nilesh), Cavalieri, E. (Ercole), Dahut, W.L. (William), Sackett, D.L. (Dan), Figg, W.D. (William), Sparreboom, A. (Alex), Sissung, T.M. (Tristan), Danesi, R. (Romano), Price, D.K. (Douglas), Steinberg, S.M. (Seth), Wit, R. (Ronald) de, Zahid, M. (Muhammad), Gaikwad, N. (Nilesh), Cavalieri, E. (Ercole), Dahut, W.L. (William), Sackett, D.L. (Dan), Figg, W.D. (William), and Sparreboom, A. (Alex)

Abstract

Using a single nucleotide polymorphism association study in 52 men with prostate cancer receiving docetaxel, we found that individuals carrying two copies of the CYP1B1*3 polymorphic variant had a poor prognosis after docetaxel-based therapies compared with individuals carrying at least one copy of the CYP1B1*1 allele (30.6 versus 12.8 months; P = 0.0004). The association between CYP1B1*3 and response to therapy was not observed in similar subjects receiving non-taxane-based therapy (P = 0.18). The systemic clearance of docetaxel was also unrelated to CYP1B1 genotype status (P = 0.39), indicating that the association of CYP1B1*3 with clinical response is not due to docetaxel metabolism. To explain these results, we hypothesized that an indirect gene-drug interaction was interfering with the primary mechanism of action of docetaxel, tubulin polymerization. We therefore conducted tubulin polymerization experiments with taxanes in the presence or absence of certain CYP1B1 estrogen metabolites, which are known to bind to nucleophilic sites in proteins and DNA, that revealed the primary estrogen metabolite of CYP1B1, 4-hydroxyestradiol (4-OHE2), when oxidized to estradiol-3,4-quinone strongly inhibits tubulin polymerization. The 4-OHE2 is also formed more readily by the protein encoded by the CYP1B1*3 allele, validating further our data in patients. Furthermore, estradiol-3,4-quinone reacted in vitro with docetaxel to form the 4-OHE2-docetaxel adduct. This pilot study provides evidence that CYP1B1*3 may be an important marker for estimating docetaxel efficacy in patients with prostate cancer. This link is likely associated with CYP1B1*3 genotype-dependent estrogen metabolism. Copyright

Published
2008
Full Text
View/download PDF

32. Natural History of Retained Surgical Items: Results of A Multi-center Study

Author

Stawicki, S.P., primary, Anderson, H.L., additional, Coyle, S.M., additional, Ahmed, H.M., additional, Chowayou, L., additional, Marchigiani, R., additional, Cipolla, J., additional, Gracias, V.H., additional, Moffatt-Bruce, S.D., additional, Seamon, M.J., additional, Adams, R.C., additional, Steinberg, S.M., additional, Stehly, C., additional, and Cook, C.H., additional

Published
2013
Full Text
View/download PDF

33. Intentional Foreign Object Ingestions: Determining Factors Associated with Hospital Admission, Therapeutic Endoscopy, and Surgery

Author

Dalal, P.P., primary, Otey, A.J., additional, McGonagle, E.A., additional, Whitmill, M.L., additional, Thomas, A.C., additional, Cook, C.H., additional, Papadimos, T.J., additional, Reilley, T.E., additional, Bergese, S.D., additional, Steinberg, S.M., additional, Stawicki, S.P., additional, and Evans, D.C., additional

Published
2013
Full Text
View/download PDF

34. Splenectomy Correlates With Worse Survival Independent of Disease Burden After Cytoreduction and Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

Author

Schaub, N.P., primary, Alimchandani, M., additional, Quezado, M., additional, Steinberg, S.M., additional, Langan, R., additional, Hughes, M.M., additional, Beresnev, T., additional, Bartlett, D.L., additional, Libutti, S.K., additional, Pingpank, J.F., additional, Royal, R.E., additional, Brcher, B., additional, Pandalai, P., additional, Phan, G.Q., additional, Stojadinovich, A., additional, Rudloff, U., additional, Alexander, H.R., additional, and Avital, I., additional

Published
2013
Full Text
View/download PDF

36. Oral Chronic Graft-vs.-Host Disease Characterization Using the NIH Scale

Author

Fassil, H., primary, Bassim, C.W., additional, Mays, J., additional, Edwards, D., additional, Baird, K., additional, Steinberg, S.M., additional, Williams, K.M., additional, Cowen, E.W., additional, Mitchell, S.A., additional, Hakim, F.T., additional, Taylor, T., additional, Avila, D., additional, Zhang, D., additional, Grkovic, L., additional, Datiles, M., additional, Gress, R.E., additional, and Pavletic, S.Z., additional

Published
2012
Full Text
View/download PDF

40. T-Rapa Cell DLI Safely Balances Th1/Th2 Cytokine Activation After Low-Intensity Allogeneic Hematopoietic Cell Transplantation

Author

Fowler, D.H., primary, Mossoba, M.E., additional, Hakim, F.T., additional, Kurlander, R., additional, Gea-Banacloche, J., additional, Sportes, C., additional, Hardy, N.M., additional, Pavletic, S.Z., additional, Steinberg, S.M., additional, Khuu, H.M., additional, Sabatino, M., additional, Stroncek, D.F., additional, Leitman, S.F., additional, Rowley, S.D., additional, Donato, M., additional, Goy, A., additional, Friedman, T.M., additional, Korngold, R., additional, Pecora, A.L., additional, Levine, B.L., additional, June, C.H., additional, Gress, R.E., additional, and Bishop, M.R., additional

Published
2011
Full Text
View/download PDF

41. Validation of the National Institutes of Health (NIH) Consensus Criteria for Chronic GVHD (cGVHD) Staging Correlated With Established Indicators of Disease Severity and Prognosis

Author

Baird, K., primary, Steinberg, S.M., additional, Grkovic, L., additional, Pulanic, D., additional, Cowen, E.W., additional, Mitchell, S.A., additional, Williams, K.M., additional, Datiles, M., additional, Fall-Dickson, J.M., additional, Carpenter, A., additional, Avila, D.N., additional, Taylor, T., additional, Urban, A., additional, Joe, G., additional, Comis, L., additional, Berger, A., additional, Stratton, P., additional, Shelhamer, J., additional, Gea-Banacloche, J., additional, Sportes, C., additional, Fowler, D.H., additional, Bishop, M.R., additional, Gress, R.E., additional, and Pavletic, S.Z., additional

Published
2011
Full Text
View/download PDF

42. NHANES III Equations for PFT Interpretation Significantly Alters BOS Diagnoses, Severity, and Prognosis After Hematopoietic Stem Cell Transplantation (HSCT)

Author

Williams, K.M., primary, Hnatiuk, O., additional, Steinberg, S.M., additional, Mitchell, S., additional, Baird, K., additional, Gadalla, S.M., additional, Carpenter, A., additional, Avila, D., additional, Taylor, T., additional, Urban, A., additional, Comis, L.E., additional, Blacklock-Schuver, B., additional, Gress, R.E., additional, and Pavletic, S.Z., additional

Published
2011
Full Text
View/download PDF

43. Hepatic Resection For Metastatic Renal Cell Carcinoma

Author

Langan, R.C., primary, Ripley, R.T., additional, Davis, J., additional, Prieto, P.A., additional, Datrice, N., additional, Steinberg, S.M., additional, Bratslavsky, G., additional, Rudloff, U., additional, Kammula, U.S., additional, and Avital, I., additional

Published
2011
Full Text
View/download PDF

44. Role of Clinical Laboratory Markers of inflammation in Assessing Chronic Graft Versus Host Disease (cGVHD) Activity and Severity

Author

Grkovic, L., primary, Baird, K., additional, Steinberg, S.M., additional, Pulanic, D., additional, Cowen, E.W., additional, Mitchell, S.A., additional, Williams, K.M., additional, Carpenter, A.E., additional, Wroblewski, S.G., additional, Hakim, F.T., additional, Avila, D.N., additional, Taylor, T.N., additional, Rowley, S.D., additional, Zhang, D., additional, Gea-Banachloche, J.C., additional, Sportes, C., additional, Fowler, D.H., additional, Bishop, M.R., additional, Gress, R.E., additional, and Pavletic, S.Z., additional

Published
2011
Full Text
View/download PDF

49. Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

Author

Schrump, D.S., primary, Fischette, M.R., additional, Nguyen, D.M., additional, Zhao, M., additional, Li, X., additional, Kunst, T.F., additional, Hancox, A., additional, Hong, J.A., additional, Chen, G.A., additional, Kruchin, E., additional, Wright, J.J., additional, Rosing, D.R., additional, Sparreboom, A., additional, Figg, W.D., additional, and Steinberg, S.M., additional

Published
2007
Full Text
View/download PDF

50. Development of graft-versus-host disease depends upon establishment of complete donor T cell chimerism after T cell depleted, reduced intensity hematopoietic stem cell transplantation

Author

Hardy, N.M., primary, Steinberg, S.M., additional, Krumlauf, M., additional, Cvitkovic, R., additional, Castro, K., additional, Hakim, F., additional, Carter, C., additional, Read, E.J., additional, Leitman, S., additional, Gress, R., additional, and Bishop, M.R., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results